OrbiMed

Ottimo Pharma focuses on creating pioneering cancer treatments for solid tumors, specifically through its lead program, Jankistomig, a bi-functional antibody targeting immune checkpoints and angiogenesis. The company aims to enhance treatment outcomes and alleviate healthcare burdens by advancing this dual-pathway approach.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Valneva is a pharmaceutical company specializing in the development of prophylactic vaccines aimed at addressing infectious diseases with significant unmet medical needs. The company has successfully commercialized several vaccines, including IXIARO/JESPECT, DUKORAL, and IXCHIQ, primarily targeting travelers. In addition to its marketed products, Valneva is advancing a diverse pipeline of vaccine candidates, including those for Lyme disease, chikungunya, and COVID-19. The company is involved in the entire lifecycle of vaccine development, encompassing research, manufacturing, and distribution. Valneva also offers technologies and services aimed at enhancing vaccine commercialization, which further supports its mission to deliver life-saving immunizations globally.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

PierianDx, Inc. is a company that specializes in developing a cloud-based genomic software solution aimed at managing, analyzing, and interpreting complex genomic tests for clinical laboratories in the United States. Founded in 2014 and headquartered in Saint Louis, Missouri, PierianDx offers the Clinical Genomicist Workstation, a comprehensive platform that oversees patient case management, including accessioning, sequencing, analysis, and reporting, while ensuring integration with electronic health records. The company caters to health systems, children’s hospitals, comprehensive cancer centers, and reference laboratories, and provides consulting and technical services. PierianDx plays a pivotal role in enhancing the utilization of genomic sequencing in healthcare, enabling physicians to improve diagnosis and treatment for cancer and other complex diseases through its accredited laboratory and shared knowledgebase.

PharmEasy is a health tech startup founded in 2015 by Dharmil Sheth, Mikhil Innani, and Dhaval Shah, operating as a subsidiary of Ascent Health. The company offers an online platform that streamlines the supply chain of pharmaceuticals by digitizing the process of medicine delivery. It provides services such as teleconsultation, medicine deliveries, and diagnostic test sample collections, facilitating connections between patients and local pharmacy stores and diagnostic centers. By improving accessibility and affordability, PharmEasy aims to meet extensive medical needs and enhance the overall healthcare experience for its users. The startup is backed by several prominent investors, including Caisse de Dépôt et Placement du Québec, Bessemer Venture Partners, and Temasek Holdings.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. The company specializes in designing acellular extracellular matrices, which are crafted in vitro from banked vascular smooth muscle cells and decellularized to prevent rejection. These products serve as tissue-engineered grafts for patients requiring vascular repair or replacement. Humacyte's innovative approach aims to provide universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while enhancing patient care and transforming medical practices. Founded in 2004, the company is committed to advancing solutions for vascular diseases and the replacement of anatomical conduits.

Rimag is a Shenzhen-based company specializing in medical imaging services. Founded in 2014, it operates medical imaging centers that provide examination and diagnostic services, including MRI, CT, PET, X-ray, ultrasound, and mammography. In addition to its imaging center operations, Rimag is involved in the development of relevant cloud technology and the training of professionals in the field. The company generates revenue through its comprehensive range of services, including Imaging Center Services, Imaging Solution Services, and Rimag Cloud Services.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

EDDA Technology specializes in computer-assisted solutions for patient care management, focusing on enhancing the efficiency and effectiveness of imaging-guided cancer treatment. The company has developed the IQQA platform, which provides innovative imaging solutions that improve workflow and patient care in various surgical contexts, including open, minimally invasive, and robotic surgeries. The platform promotes a patient-specific and disease-targeted approach, facilitating a multidisciplinary strategy for cancer treatment. It supports the entire surgical process, including pre-surgical planning and simulation, intra-operative guidance and monitoring, post-operative follow-up, and training. By enabling advanced clinical applications such as automated volumetric organ segmentation and virtual treatment simulation, EDDA Technology aims to improve early disease detection and diagnosis, ultimately enhancing patient outcomes.

Crossover Health, Inc. provides comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010, the company is headquartered in Aliso Viejo, California, with health centers located in various regions, including Silicon Valley. Crossover Health offers a wide range of services, including primary care, urgent care, chronic disease management, preventive care, health risk assessments, and health education. Additionally, it provides ancillary services such as physical therapy, chiropractic care, acupuncture, and care coordination, along with health analytics and remote care options. The company's focus is on creating a positive employee care experience that promotes a healthy and motivated workforce while delivering financial benefits to organizations.

Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

CoreMap, Inc. is dedicated to enhancing patient outcomes through advanced diagnostic technology tailored for electrophysiologists treating atrial fibrillation. Founded in 2016 and based in Winooski, Vermont, the company has developed a micro-electrode solution that allows for sequential mapping of tissue properties. This innovative technology addresses critical challenges in atrial fibrillation treatment, specifically poor spatial resolution and inadequate sample density. CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even in the presence of fibrillation, thereby enabling medical practitioners to offer more effective treatment options for patients.

MobileODT Ltd develops optical diagnostic devices and software services aimed at early cancer detection. The company offers the EVA COLPO, a portable and FDA-cleared colposcope that connects to the internet, making it easy for healthcare providers to conduct examinations. The EVA SANE system allows for the secure management of patient data, including photos and notes, on a HIPAA-compliant server. Additionally, the EVA WELL tool enhances gynecologic exams through digital visualization. MobileODT also provides a mobile application for remote image capture and patient information tracking, alongside a cloud-based portal for collaboration and reporting. Other products include Eviscope, designed for documenting violence and abuse, EviDx for case documentation, and EviCenter for managing patient data. Founded in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has established a strong presence in markets such as the U.S., Africa, and India, having conducted over 40,000 procedures across 29 countries.

Perfuse Therapeutics specializes in developing therapies for the treatment of eye disease. The company is pursuing a novel mechanism to treat various eye diseases, starting with glaucoma, by improving retinal perfusion.

New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Jinxin Fertility Group Limited is a prominent provider of assisted reproductive services (ARS) in China and the United States, established in 2003 and headquartered in Chengdu, China. The company offers a range of treatment options, including artificial insemination with either the husband's sperm or donor sperm, as well as in vitro fertilization (IVF) techniques such as conventional IVF and intracytoplasmic sperm injection (ICSI). In addition to these core services, Jinxin Fertility provides various supportive services, including nutritional guidance, traditional Chinese medicine, and psychological counseling, to enhance the patient experience. The organization operates through several subsidiaries, including Chengdu Xinan and Shenzhen Zhongshan, and has expanded its network to deliver high-quality reproductive health services. Jinxin Fertility primarily derives its revenue from its ARS offerings, along with management and ancillary medical services, with a significant portion of its income coming from the Chinese market.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

MobileODT Ltd develops optical diagnostic devices and software services aimed at early cancer detection. The company offers the EVA COLPO, a portable and FDA-cleared colposcope that connects to the internet, making it easy for healthcare providers to conduct examinations. The EVA SANE system allows for the secure management of patient data, including photos and notes, on a HIPAA-compliant server. Additionally, the EVA WELL tool enhances gynecologic exams through digital visualization. MobileODT also provides a mobile application for remote image capture and patient information tracking, alongside a cloud-based portal for collaboration and reporting. Other products include Eviscope, designed for documenting violence and abuse, EviDx for case documentation, and EviCenter for managing patient data. Founded in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has established a strong presence in markets such as the U.S., Africa, and India, having conducted over 40,000 procedures across 29 countries.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Suraksha Diagnostics, established in 1992 in Kolkata, is a prominent provider of comprehensive pathology and radiology services. As one of the earliest diagnostic centers in the region, it has gained a reputation for accuracy and high-quality service. The company expanded rapidly, opening a second facility in Siliguri within three years, which has since become the largest diagnostic center in North Bengal, catering to patients from the surrounding areas and neighboring states. Suraksha Diagnostics continues to grow its footprint across Bengal, Bihar, and the Delhi NCR, offering specialized diagnostic tests in areas such as imaging, cardiology, neurology, and gastroenterology. The organization aims to enhance industry standards through a robust network of laboratory and imaging services, along with tailored offerings for its clientele.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Eurolife Healthcare is a manufacturer and distributor of a diverse array of healthcare formulations tailored for various medical applications. The company specializes in producing generic pharmaceutical products, including intravenous infusions, ophthalmic solutions, sterilized water for injections, tablets, capsules, ointments, creams, and other formulations. Eurolife Healthcare emphasizes high-quality and sterile packaging to ensure that healthcare providers can effectively meet medical supply demands. Its product offerings extend to systems such as the eurohead infusion system, classic infusion therapy, and specialized solutions like Lifeflow and Germkill, designed to address specific therapeutic needs in the healthcare sector.

TigerConnect is a healthcare communications platform that enhances collaboration among doctors, nurses, care teams, and patients through real-time mobile messaging. Founded in 2010 and headquartered in Santa Monica, California, the company offers a user-friendly interface that integrates text, video, and voice communication while ensuring high levels of security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and maintains a 99.99% uptime. Its innovative solutions and seamless integration with critical hospital systems help healthcare providers improve productivity, reduce costs, and enhance patient outcomes. The company is dedicated to client success, providing comprehensive support to optimize communication workflows and maximize return on investment.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Sikka.ai provides a cloud-based platform designed to transform the retail healthcare market, focusing on non-physician practices such as dentistry, veterinary care, optometry, chiropractic, orthodontics, and oral surgery. The company's award-winning single API platform leverages artificial intelligence and predictive analytics to connect with 96% of the retail healthcare market. With over 35,000 practice installations and 120 million patients on its platform, Sikka.ai facilitates the integration of various practice management and financial systems, enabling healthcare providers to optimize their operations. The platform features 50 applications developed by various suppliers, including Fortune 500 companies, along with four proprietary applications. Sikka.ai aims to create a real-time global platform that empowers patients, providers, and suppliers, addressing a market with an annual services expenditure exceeding $260 billion. The company’s innovative approach was recognized with the Best Health API Award in 2019.

Natera, Inc. is a diagnostic company that specializes in preconception and prenatal genetic testing services. Its primary offerings include the Panorama test, which is a non-invasive prenatal test that screens for chromosomal abnormalities in a fetus through a blood sample from the mother, and the Vistara test, designed to identify single-gene disorders. Additionally, Natera provides Horizon carrier screening to determine genetic disease carrier status and Spectrum, which analyzes chromosomal anomalies during in vitro fertilization. The company also offers Anora, a test for analyzing fetal chromosomes to investigate miscarriage causes, and non-invasive paternity testing. Its Signatera product utilizes circulating tumor DNA technology to monitor cancer recurrence. Natera markets its tests through a direct sales force and a network of approximately 100 laboratory and distribution partners both domestically and internationally. The company, founded in 2003 and headquartered in San Carlos, California, maintains partnerships with BGI Genomics and Foundation Medicine for the development of genetic testing assays.

Rapid Pathogen Screening, Inc. is a biotechnology company based in Sarasota, Florida, founded in 2004. It specializes in developing, manufacturing, and marketing rapid point-of-care diagnostic tests aimed at identifying infectious diseases, inflammatory conditions, and threats from bio-terrorism and chemical nerve agents. The company's product portfolio includes AdenoPlus, which detects various serotypes of adenoviral conjunctivitis, and InflammaDry, a test for dry eye, both of which are available to healthcare professionals in the United States and internationally. Rapid Pathogen Screening utilizes a patented technology platform that ensures high sensitivity and specificity in its tests, enabling healthcare providers to conduct accurate diagnoses with minimal training and equipment. The company distributes its products through various channels, underscoring its commitment to improving patient health and reducing healthcare costs associated with disease management.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.

TigerConnect is a healthcare communications platform that enhances collaboration among doctors, nurses, care teams, and patients through real-time mobile messaging. Founded in 2010 and headquartered in Santa Monica, California, the company offers a user-friendly interface that integrates text, video, and voice communication while ensuring high levels of security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and maintains a 99.99% uptime. Its innovative solutions and seamless integration with critical hospital systems help healthcare providers improve productivity, reduce costs, and enhance patient outcomes. The company is dedicated to client success, providing comprehensive support to optimize communication workflows and maximize return on investment.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company headquartered in Tel Aviv, Israel, focusing on gastrointestinal and infectious diseases. The company markets several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for Helicobacter pylori infection, and Aemcolo for travelers' diarrhea. RedHill is also engaged in late-stage clinical development programs, which include RHB-204 for pulmonary nontuberculous mycobacteria infections, RHB-104 for Crohn's disease, and RHB-102 (Bekinda) for acute gastroenteritis and gastritis. Additionally, it is developing opaganib, a selective inhibitor with ongoing studies for various conditions, including COVID-19 and cancer. Other investigational products include RHB-107, aimed at treating cancer and inflammatory gastrointestinal diseases, and RHB-106, an encapsulated bowel preparation. Established in 2009, RedHill aims to innovate and enhance treatment options in its specialized fields.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Practice Fusion, Inc. is a cloud-based electronic health records (EHR) company based in San Francisco, California, founded in 2005. The company provides a comprehensive practice management software platform that includes features such as charting, scheduling, billing, e-prescribing, lab integrations, and secure messaging. This platform is designed to connect medical professionals, patients, labs, billers, imaging centers, and life science partners, facilitating improved healthcare delivery. Additionally, Practice Fusion offers a healthcare database called Practice Fusion Insight to support medical professionals. Its services cater to a diverse range of users, including independent practices, community clinics, large medical groups, and non-profit organizations. As of February 2018, Practice Fusion operates as a subsidiary of Allscripts Healthcare Solutions.

Amoy Diagnostics is a research and development based diagnostic company focusing on molecular diagnostics for oncology precision medicine. AmoyDx has a portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems.

Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Natera, Inc. is a diagnostic company that specializes in preconception and prenatal genetic testing services. Its primary offerings include the Panorama test, which is a non-invasive prenatal test that screens for chromosomal abnormalities in a fetus through a blood sample from the mother, and the Vistara test, designed to identify single-gene disorders. Additionally, Natera provides Horizon carrier screening to determine genetic disease carrier status and Spectrum, which analyzes chromosomal anomalies during in vitro fertilization. The company also offers Anora, a test for analyzing fetal chromosomes to investigate miscarriage causes, and non-invasive paternity testing. Its Signatera product utilizes circulating tumor DNA technology to monitor cancer recurrence. Natera markets its tests through a direct sales force and a network of approximately 100 laboratory and distribution partners both domestically and internationally. The company, founded in 2003 and headquartered in San Carlos, California, maintains partnerships with BGI Genomics and Foundation Medicine for the development of genetic testing assays.

Treato Ltd. operates a health information platform that aggregates and analyzes patient experiences sourced from the Internet, particularly from social media sites and forums. The platform provides valuable insights for patients, healthcare professionals, pharmaceutical companies, and other healthcare organizations. By employing advanced Natural Language Processing, Treato extracts relevant information from the vast amount of patient-written health experiences, creating a comprehensive understanding of public sentiment regarding medications and health conditions. Treato also offers Treato Pharma, a specialized service that delivers real-time analytics and insights to pharmaceutical marketers, helping them interpret patient opinions, understand competitive dynamics, and enhance patient engagement. Founded in 2008 and based in Yehud, Israel, Treato serves as a critical resource for both consumers and the healthcare industry, with its advertising-free consumer site attracting hundreds of thousands of users weekly.

CardiAQ Valve Technologies is a privately held company specializing in advanced solutions for heart valve replacement, with a primary focus on transcatheter mitral valve implantation (TMVI). The company has developed a system that allows physicians to implant a mitral valve within a beating heart, thereby eliminating the need for open-heart surgery. This innovative approach aims to enhance patient outcomes and simplify the procedure for both patients and healthcare providers.

Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.

Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

The Kerala Institute of Medical Sciences is a multi-specialty tertiary care hospital located in Thiruvananthapuram, India, dedicated to providing high-quality medical services through a combination of specialist expertise and advanced technology. Founded in 2002, the institution focuses on making healthcare accessible and affordable for the community. It encompasses a range of services from primary to quaternary care, including health check programs and emergency services. In addition to its hospital operations, the Kerala Institute of Medical Sciences is involved in medical education, offering specialized courses for nurses and postgraduate programs for doctors, including 20 DNB programmes and various fellowship courses. The organization also features a College of Nursing and an Institute of Skill Development and Paramedical Institute, reflecting its commitment to quality patient care, research, and education.

Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

Innovative Spinal Technologies is a spine technology company based in Mansfield, Massachusetts, that specializes in developing motion preservation and minimally invasive treatments for spinal disorders. Founded in 2002, the company offers a range of products designed to enhance surgical outcomes in spinal procedures. Its AXIENT Dynamic Fixation system is a pedicle screw-based motion system, while the PARAMOUNT product line includes several systems tailored for lumbar fusion procedures. This includes the PARAMOUNT Lumbar Fusion System, which can be used in minimally invasive, mini-open, or open surgical techniques, as well as the PARAMOUNT MIS and Open Pedicle Screw Systems, designed for single and multi-level procedures. Additionally, the PARAMOUNT VBR is engineered for a minimally invasive transforaminal approach.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. The company utilizes a mechanobiology technology platform to create its lead product, Gelesis100, an orally administered smart pill that contains hydrogel particles. This product is designed to expand in the stomach, promoting a feeling of fullness and aiding in weight management. Gelesis also offers PLENITY, an FDA-cleared product that assists individuals with weight management. In addition to these offerings, Gelesis has a pipeline of potential therapeutics targeting conditions such as Type 2 diabetes, non-alcoholic fatty liver disease, and chronic idiopathic constipation. Established in 2006, Gelesis aims to provide safe and effective solutions for patients dealing with obesity and related health issues.

Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.